JYP0035 / Guangzhou JOYO Pharma - LARVOL DELTA

First-in-human study of JYP0035, a highly selective PI3Kα inhibitor, as monotherapy in patients with advanced solid tumors (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • Monotherapy • P1 data • Oncology • Solid Tumor • PIK3CA

JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=171 | Not yet recruiting | Sponsor: Chengdu JOYO pharma Co., Ltd.

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR • PIK3CA

A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: Chengdu JOYO pharma Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Enrollment open • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor